IR (Infrared) 24-hour amplitude at 118.0%: Trading volume surge triggers speculative volatility
Bitget Pulse2026/05/07 16:02Volatility Overview
IR experienced significant price volatility in the past 24 hours, with a high of $0.03477 and a low of $0.01595. The current price is $0.01812, reflecting a fluctuation amplitude of 118.0%. The 24-hour trading volume surged to $5.82 million (Vol/MC ratio of 159.3%), with a total market capitalization of $3.65 million and around 15,500 holder addresses.
Brief Analysis of Abnormal Movement Causes
- Trading volume soared: According to Bitget Pulse at 15:49 on May 6, 2026, IR's 24-hour trading volume spiked, pushing the price from $0.01595 to $0.03477.
- No direct catalyst: There were no official announcements, project updates, new listings, or on-chain large whale transactions. The abnormal movement was mainly driven by speculative trading and a trading volume peak.
Market Views and Outlook
Market discussions regarding IR's movement are limited, with no prominent discussions or in-depth analyst interpretations observed on mainstream data platforms. The current price is retracing (down approximately 6.5% in 24 hours), while the high Vol/MC suggests elevated speculative risk. In the short term, volatility may persist. Investors should monitor changes in trading volume and liquidity (Liq/MC 10.24%).
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
